Jianerkang Medical Co (SHSE:603205) EBIT: ¥127 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603205 Jianerkang Medical Co Ltd SHSE:603205
31 GF Score
Price ¥20.36
! 3 Warning Signs
View Full Analysis

What is Jianerkang Medical Co EBIT?

Jianerkang Medical Co SHSE:603205 +0.99% 31 EBIT is ¥127 Mil as of Mar. 2026. GuruFocus rates SHSE:603205 with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Jianerkang Medical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥32 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥127 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jianerkang Medical Co's annualized ROC % for the quarter that ended in Mar. 2026 was 14.58%. Jianerkang Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jianerkang Medical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.32%.


Jianerkang Medical Co  (SHSE:603205) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jianerkang Medical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=132.412 * ( 1 - 12.1% )/( (790.111 + 806.774)/ 2 )
=116.390148/798.4425
=14.58 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1710.616 - 155.591 - ( 764.914 - max(0, 167.176 - 1209.606+764.914))
=790.111

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1700.22 - 121.054 - ( 772.392 - max(0, 130.621 - 1196.718+772.392))
=806.774

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Jianerkang Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=126.616/( ( (380.051 + max(262.849, 0)) + (381.994 + max(280.857, 0)) )/ 2 )
=126.616/( ( 642.9 + 662.851 )/ 2 )
=126.616/652.8755
=19.39 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(244.779 + 167.022 + 12.999) - (155.591 + 0 + 6.36)
=262.849

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(204.472 + 181.7 + 21.36) - (121.054 + 0 + 5.621)
=280.857

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jianerkang Medical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=127.233/2391.627
=5.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jianerkang Medical Co EBIT Related Terms


Jianerkang Medical Co EBIT Historical Data

* Premium members only.

The historical data trend for Jianerkang Medical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jianerkang Medical Co EBIT Chart

Jianerkang Medical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 157.91 184.46 143.93 137.70 127.55

Jianerkang Medical Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.97 22.80 32.56 40.22 31.65

SHSE:603205 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Jianerkang Medical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jianerkang Medical Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jianerkang Medical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jianerkang Medical Co's EV-to-EBIT falls into.


SHSE:603205
31GF Score
Jianerkang Medical Co Ltd SHSE:603205
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jianerkang Medical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥127 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥127 Mil mean?
Jianerkang Medical Co (SHSE:603205) has a EBIT of ¥127 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Jianerkang Medical Co.
Is Jianerkang Medical Co's EBIT too high?
Jianerkang Medical Co's current EBIT is ¥127 Mil. Overall, Jianerkang Medical Co has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Jianerkang Medical Co's EBIT compare to ISRG and BDX?
Jianerkang Medical Co's EBIT of ¥127 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Jianerkang Medical Co. Jianerkang Medical Co's current EBIT is ¥127 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jianerkang Medical Co stock overvalued right now?
Jianerkang Medical Co (SHSE:603205) has a current EBIT of ¥127 Mil. The current EBIT is ¥127 Mil. Jianerkang Medical Co's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Jianerkang Medical Co (SHSE:603205), the current EBIT is ¥127 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jianerkang Medical Co Business Description

Address No. 1, Jianerkang Road, Industrial Concentration Zone, Zhixi Town, Jintan District, Jiangsu Province, Changzhou, CHN, 213251
Jianerkang Medical Co Ltd is engaged in research and development, production and sales of disposable medical devices such as medical dressings and disinfection and hygiene products.
31GF Score

Get the complete analysis for SHSE:603205

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥20.36
Price